Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine : a voxel-based morphometry study

Details

Serval ID
serval:BIB_2A03065944A9
Type
Article: article from journal or magazin.
Collection
Publications
Title
Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine : a voxel-based morphometry study
Journal
International clinical psychopharmacology
Author(s)
Stip E., Mancini-Marïe A., Letourneau G., Fahim C., Mensour B., Crivello F., Dollfus S.
ISSN
0268-1315
Publication state
Published
Issued date
2009
Volume
24
Number
1
Pages
34-41
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Abstract
Among new-generation antipsychotics, quetiapine was found to be associated with a partial 'normalization' of reduced functional activation in prefrontal and temporal areas and studies conducted by our group found a clinical improvement in negative symptoms in addition to restoration of frontal activation in schizophrenia patients with blunted affect after treatment with quetiapine. Here we investigated the parallelism between improved clinical symptoms and grey mater density (GMD) changes in the frontal region after quetiapine treatment in 15 schizophrenia patients. We hypothesize that improvement in clinical symptoms will be associated with change in GMD in prefrontal regions of interest. By using voxel-based morphometry, paired t-test random-effect analysis showed a significant increase in GMD bilaterally in the inferior frontal cortex/orbitofrontal gyrus and anterior cingulate cortex after 5.5 months of treatment with quetiapine. This GMD increase was associated with a significant improvement in negative symptoms. When GMD was correlated with psychiatric assessment scores, there was a negative correlation between GMD in the anterior cingulate cortex and the Rating Scale for Emotional Blunting score (r=-665, P=0.008) and between the orbitofrontal gyrus and the total Positive and Negative Syndrome Scale negative score (r=-764, P=0.001). Results suggest that increased GMD in some frontal regions are associated with an improvement of negative symptoms. Although not unique to quetiapine, it would be reasonable to attribute the GMD changes in the study to treatment.
Keywords
Adult, Antipsychotic Agents / pharmacology, Antipsychotic Agents / therapeutic use, Brain / drug effects, Brain / pathology, Caudate Nucleus / drug effects, Caudate Nucleus / pathology, Dibenzothiazepines / pharmacology, Dibenzothiazepines / therapeutic use, Female, Frontal Lobe / drug effects, Frontal Lobe / pathology, Gyrus Cinguli / drug effects, Gyrus Cinguli / pathology, Hippocampus / drug effects, Hippocampus / pathology, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Schizophrenia / drug therapy, Schizophrenia / pathology, Temporal Lobe / drug effects, Temporal Lobe / pathology, Young Adult
Pubmed
Create date
24/06/2009 13:36
Last modification date
20/08/2019 13:09
Usage data